Ryan Livingston

CaRi-Heart measures coronary inflammation from routine CT angiography and generates a personalized 10-year cardiovascular mortality risk score.

The FDA has officially granted Fast Track designation to HTX-001 for the treatment of non-obstructive hypertrophic cardiomyopathy.

The Voluntary Sodium Reduction Goals, issued in October 2021, resulted in no significant reduction in sodium content among packaged foods.

Retatrutide met 80-week weight-loss endpoints in TRIUMPH-2 and TRIUMPH-3, prompting a planned FDA submission in Q1 2027.

If approved, encaleret will be the first treatment specifically indicated for this underrepresented patient population.

According to a recent study, nearly 32.2% of US adults are well above their LDL-C targets to avoid atherosclerotic cardiovascular disease.

After broadening eligibility criteria across several disease states and a wider age range, the new guidelines have made an estimated 87.5 million adults eligible for statins.

FDA accepted Camurus’ resubmitted CAM2029 application for acromegaly, with a target action date of December 18, 2026.

A recent analysis of data from the Global Burden of Disease Study has indicated a relationship between risk of death from ACHD and socioeconomic factors.

FDA approved once-daily oral enlicitide to lower LDL-C in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia.

These modifiable factors, among others, directly contribute to 88.7% of all IHD deaths in 2023.

New data from the 45-patient Midpoint Cohort, despite not being powered for statistical significance, indicate a potentially substantial benefit.

Eplontersen did not significantly reduce cardiovascular mortality and recurrent cardiovascular events in the phase 3 CARDIO-TTRansform trial.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 6 months.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Catch up on key FDA approvals, major trial updates, and critical clinician insights from the last 3 months.

Catch up on FDA approvals, trial readouts, and key clinician insights across the cardiology specialty.

Catch up on major trial results, groundbreaking FDA decisions, and key clinician insights from major endocrinology conferences.

The FDA has approved veligrotug-vvze for thyroid eye disease regardless of activity or duration.

A study from UC Berkeley has unveiled an AI model that outperforms standard clinical tests in identifying patients at risk of sudden cardiac death.

Corxel reported CX11 met phase 2 endpoints in adults with obesity or overweight, with up to 11.5% weight loss at 36 weeks.

Data from the ongoing open-label extensions of PATHFNDR-1 and PATHFNDR-2, presented at ENDO 2026, highlight the drug’s efficacy in reducing IGF-1.

New data presented at ENDO 2026 have indicated substantially lower basal insulin and bolus insulin dose requirements in this population following discharge.

New data from ENDO 2026 reflect the accompanying reductions in HbA1c, lipids, and other major biomarkers in patients treated with GLP-1 RAs.

New data from ENDO 2026 have indicated a statistically significant increase in hypotension and related events in adults receiving GLP-1s who are already hypertensive.

Catch up on any data and key clinician perspectives presented at the American Diabetes Association Scientific Sessions 2026.

A new substudy of VESALIUS-CV presented at ADA 2026 has confirmed that evolocumab’s cardioprotective effects extend to patients at risk from diabetes.

Eli Lilly’s investigative GLP-1/GIP/glucagon triple agonist has demonstrated its efficacy in reducing several major factors of obesity versus placebo.

Eli Lilly’s investigative GLP-1/GIP/glucagon triple agonist has outperformed placebo in patients with poorly-controlled T2D.